Sulfonamide and sulfamide substituted imidazoquinolines

Also published as: Publication number: CN1354663 (A) CN1249061 (C)
WO0076519 (A1)
US6331539 (B1)
US2003130299 (A1)
US6825350 (B2) 2002-06-19 **Publication date:** CROOKS S L [US]; LINDSTROM K J [US]; MERRILL B A Inventor(s): [US] + 3M INNOVATIVE PROPERTIES CO (US) + Applicant(s):

Classification:

- international:

A61K31/437; A61K31/4745; A61K31/496; A61K31/541;

A61K45/06; A61K9/00; A61P31/12; A61P35/00; A61P37/02; C07D471/04; A61K31/4353; A61K31/4738; A61K31/496; A61K31/541; A61K45/00; A61K9/00; A61P31/00; A61P35/00; A61P37/00; C07D471/00; (IPC1more >>

7): A61K31/437; A61K31/4745; C07D471/02

- European: A61K31/4745; A61K45/06; A61K9/00M18D; A61K9/00M18E;

C07D471/04; A61K31/4745

Application number: CN20008008683 20000608

Priority number(s): US19990138365P 19990610; US20000589216 20000607

Abstract not available for CN 1354663 (A)

Abstract of corresponding document: WO 0076519 (A1)

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Data supplied from the *espacenet* database — Worldwide